Autism clinical trials: biological and medical issues in patient selection and treatment response.
Biomedical measures are critical in the initial patient-screening and -selection phases of a clinical trial in autism and related disorders. These measures can also play an important role in the assessment and characterization of response and can provide an opportunity to study underlying etiologic and pathophysiologic processes. Thus, biomedical measures, including clinical laboratory analyses, metabolic screening, and chromosomal analysis, are used to screen for potential safety-related problems, to decrease biological and genetic heterogeneity, and to define subgroups. Neurobiological measures can be examined as possible predictors, modifiers or surrogates of therapeutic response, and adverse effects. Neurobiological research measures can also be used to study mechanisms and extent of drug action and to perform baseline and longitudinal investigations of possible pathophysiologic alterations. The potential utility and desirability of specific measures are considered and the general approach to choosing measures for incorporation is discussed.
Department of Child Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. george.anderson@yale.edu
George M
GM
Anderson
Andrew W
AW
Zimmerman
Natacha
N
Akshoomoff
Diane C
DC
Chugani
D001321:Autistic Disorder / Q000188:drug therapy*; D015415:Biomarkers; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D018579:Patient Selection; D016896:Treatment Outcome
D015415:Biomarkers